EN DE

TELES Informationstechnologien AG (TLIK) Fair Value & Analysis

Healthcare · DE · Market cap €3.8M · ISIN DE000A289B07

What is TELES Informationstechnologien AG really worth?

TI TELES Informationstechnologien AG TLIK · XETRA
Price€0.2060
Fair Value€0.2256
Upside+9.5%
Quality31/100

Below-average quality, currently priced close to our fair value of €0.2256.

Watch TELES Informationstechnologien AG for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Risks

!Weak Growth (revenue 5y −30.9 %/yr)
!Thin margins · 0.0% net margin
!negative free cash flow
!Trails peers (2/7)
!Narrow moat 0/100
!Evidence only low, so the estimate is less certain
Evidence: Low Range €0.1126 – €0.3435

Fair value as of: Jul 17, 2026

From 2 valuation models · updated 45 days ago

Fair value updated Jul 17, 2026, revised from €59.99 to €0.2256 (−99.6%) since Jun 24, 2026. Share price −16.9% over the past month.

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The model range is unusually wide (€0.1126 to €0.3435). The outcome hinges heavily on assumptions, so read the point estimate with caution.
  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Price vs Fair Value (5 years)

€8.95 €0.0005 Fair Value €0.2256 Mar 2018 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.

How to read this chart

60‑month range €0.0005 – €8.95 · fair‑value band €0.1126 – €0.3435 · the €0.2060 price screens below the €0.2256 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

TELES Informationstechnologien AG (TLIK) currently trades at €0.2060, while our model-based Fair Value estimate is €0.2256, implying the stock looks roughly 8.7% fairly valued today. The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 2 models at a data quality of 91/100, which puts the evidence level at low.

Trailing-twelve-month revenue stands at €239K. It earns a return on equity of −96.8%. Fundamentals as of Jul 17, 2026

Our scenario range runs from €0.1126 (bear case) to €0.3435 (bull case); at €0.2060, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 72% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at 10%, TLIK screens cheaper than that median.

Notify me when TLIK reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

P/S ratio 15.9 TTM
EPS (TTM) €−0.1300
Net margin −127% FY2024
Return on equity −96.8% TTM
Return on assets (EBIT) −24.2% avg 5y
Operating margin −284% TTM
More key figures
Growth
Revenue (TTM) €239K TTM
Revenue growth (YoY) +384% 3y avg −36.1%
EPS growth (YoY) −98.4%
Balance sheet & cash flow
Free cash flow −€1.4M FY2024
Net debt €510K FY2024

Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 31/100

Of which business quality 31 · Market factors (momentum, volatility) 23

Profitability 7
Margins and returns on capital today
Quality Growth 39
Are margins and returns improving?
Cashflow 26
Earnings quality: real cash, not paper profit
Fin. Strength 3
Balance sheet, leverage, solvency risk
Investment 66
Disciplined investing over empire-building
Low Volatility 32
Calm price path (market factor)
Momentum 21
Price trend over the last 3–12 months (market factor)
52W Momentum 17
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Arzneiwerk AG VIDA engages in the supply of pharmaceuticals for newly developed or rare medicines in Europe. The company was formerly known as TELES Aktiengesellschaft and changed its name to Arzneiwerk AG VIDA in July 2024. The company was incorporated in 1996 and is based in Berlin, Germany.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2020 – FY2024 · reported fiscal years

TELES Informationstechnologien AG reported revenue of €658K in FY2024 versus €2.8M in FY2020, a compound −30.5%/yr. Reported net income was −€835K in FY2024.

Growth Quality 0/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2024)
€658K
Latest YoY
−98.9%
Avg. revenue growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−36.1%
Avg. revenue growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−30.9%
Avg. revenue growth/yr (21Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−20.3%
Value creation/yr We only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
not computed
Revenue −30.5%/yr
FY20 €2.8M
FY21 €2.5M
FY22 €2.2M
FY23 €59.3M
FY24 €658K
Net income
FY20 €825K
FY21 €268K
FY22 −€1.7M
FY23 −€2.9M
FY24 −€835K

Watch TLIK: get an alert when its fair value changes →

Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "TELES Informationstechnologien AG Fair Value". https://www.fairvalue-calculator.com/stock/TLIK

Peer Group

Medical Distribution · 82 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 31 · Bottom 25%
Fair Value upside +12% · Above median
Return on assets −5% · Bottom 25%
Net margin (TTM) 0% · Bottom 25%
Revenue growth 384% · Top 25%

Valuation Multiples vs Medical Distribution median · lower = cheaper

P/S (TTM) 18.49× · Pricier than 75% of peers

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE49 · sector 28
FUTURE100 · sector 16
PAST0 · sector 23
HEALTH0 · sector 97
DIVIDEND0 · sector 53

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).

Stock Price Fair Value vs Fair Value
McKesson Corporation MCK $896.65 $819.31 −9%
Cencora, Inc COR $327.79 $211.07 −36%
Cardinal Health, Inc CAH $234.55 $141.77 −40%
Henry Schein, Inc HSIC $88.46 $71.70 −19%
Shanghai Pharmaceuticals Holding 601607 ¥16.37 ¥33.96 +107%
Sinopharm Group 1099 HK$16.75 HK$58.67 +250%
Galenica AG GALE CHF 80.85 CHF 61.79 −24%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥21.03 ¥28.65 +36%
Jointown Pharmaceutical Group 600998 ¥5.04 ¥9.84 +95%
Asker Healthcare Group ASKER kr 74.40 kr 28.26 −62%

Compare TELES Informationstechnologien AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Fama-French 3-Factor Model Calculator Run the Fama-French 3-factor model in seconds: expected return from the market, size and value factors - free, with formula, betas and an example. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is TELES Informationstechnologien AG (TLIK) overvalued or undervalued?
As of Jul 17, 2026, our model estimates a fair value of €0.2256 versus a price of €0.2060, about +10% upside (fairly valued).
What is the fair value of TLIK?
Our model-based fair value for TELES Informationstechnologien AG is €0.2256 (as of Jul 17, 2026), built from audited fundamentals. The current price: €0.2060.
What is the quality score of TLIK?
TELES Informationstechnologien AG has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of TELES Informationstechnologien AG (TLIK)?
TELES Informationstechnologien AG reported trailing-twelve-month revenue of about €239K (latest available figure, as of Jul 17, 2026).
What is the net profit margin of TLIK?
The net profit margin of TELES Informationstechnologien AG is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.
Free · no account needed

Watch TELES Informationstechnologien AG in the live analysis

One click puts TELES Informationstechnologien AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.